DOCSLIB.ORG

August 21, 2019 Oversight Committee Meeting Packet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
August 21, 2019 Oversight Committee Meeting Packet Oversight Committee Meeting August 21, 2019 Oversight Committee Meeting Agenda Texas State Capitol Extension 1100 Congress Avenue, Austin, Texas 78701 Room E1.012 August 21, 2019 9:00 a.m. The Oversight Committee may discuss or act on any item on this agenda, and as authorized by the Texas Open Meetings Act, Texas Government Code Section 551.001 et seq., may meet in closed session concerning any purpose permitted by the Act. Anyone wishing to offer public comments must notify the Chief Executive Officer in writing prior to the start of the meeting. The Committee may limit the time a member of the public may speak. 1. Call to Order 2. Roll Call/Excused Absences 3. Adoption of Minutes from the May 15, 2019 meeting Tab 1 4. Public Comment 5. Grantee Presentation Tab 2 6. Chief Executive Officer Report Tab 3 7. Chief Compliance Officer Report and Compliance Certification of Grant Award Process Tab 4 8. Chief Scientific Officer Report Tab 5 • Grant Award Recommendations • Proposed FY 2020 Cycle 2 Requests for Applications 9. Chief Product Development Officer Report Tab 6 • Grant Award Recommendations • Proposed FY 2020 Cycle 2 Requests for Applications • Product Development Review Council Membership • DP180042 contract change request • DP170043 contract change request 10. Chief Prevention Officer Report Tab 7 • Grant Award Recommendations • Proposed FY 2020 Cycle 2 Requests for Applications 11. Internal Auditor Report Tab 8 • Internal Audit Follow Up Procedures Report Over Procurement and P-Cards • FY 2020 Internal Audit Plan 12. Scientific Research and Prevention Program Committee Appointments Tab 9 13. Advisory Committee Appointments Tab 10 14. FY 2020 Honoraria Policy Tab 11 15. Health & Safety Code Section 102.1062 Waivers Tab 12 16. Resolution Transferring Management Authority to the Texas Treasury Safekeeping Trust Company Tab 13 17. Amendments to 25 T.A.C. Chapter 703 Tab 14 • Final Order Approving Amendments to Chapter 703 • Proposed Amendments to Chapter 703 and Authorization to Publish in Texas Register Tab 15 18. Chief Operating Officer Report 19. Contract Approvals Tab 16 • Economic Assessment of the Cost of Cancer in Texas • Internal Auditor • Strategic Communications (contract renewal) • Due Diligence Services (contract renewal) • Grant Management Support Services (contract amendment) • Outside Legal Services (contract renewals) • Texas Treasury Safekeeping Trust Company Interagency Contract 20. Subcommittee Business Tab 17 • FY 2020 – 2021 Subcommittee assignments 21. Personnel - CEO 22. Election of Board Officers Tab 18 23. Compliance Investigation Pursuant to Health & Safety Code § 102.2631 24. Consultation with General Counsel 25. Future Meeting Dates and Agenda Items Tab 19 • FY 2020 Meeting Dates 26. Adjourn Meeting Agenda August 21, 2019 Page 2 Summary Overview of the August 21, 2019 Oversight Committee Meeting This summary provides an overview of major agenda items and background on key issues for Committee consideration at the August 21, 2019 Oversight Committee meeting. CEO Report Wayne Roberts will present the CEO’s report and address issues including a personnel update, grant funds available for FY 2019 and other topics. Chief Compliance Officer Report Vince Burgess will report on the status of required grantee reports, financial status report reviews, desk reviews and site visits, annual compliance attestation, single audit tracking, and training. Chief Scientific Officer Report and Grant Award Recommendations Dr. James Willson will provide an update on the Academic Research Program and present the Program Integration Committee’s (PIC) 59 award recommendations for Individual Investigator Awards, Core Facility Support Awards, Early Translational Research Awards, High- Impact/High-Risk Research Awards, Collaborative Action Center, Collaborative Action Program Investigated Initiated Research Awards, Recruitment of First-Time, Tenure-Track Faculty Members, Recruitment of Rising Stars, and Recruitment of Established Investigators totaling $100,929,894. Dr. Willson will also present the proposed timeline and requests for applications (RFAs) for the second cycle of FY 2020. CPRIT will not publicly disclose information related to the Academic Research grant applications recommended for funding until the Oversight Committee meeting. The information is available to board members through a secure electronic portal. Chief Product Development Officer Report and Grant Award Recommendation Dr. WalkerPeach will provide an update on the Product Development Program. She will also present the PIC’s four award recommendations for Texas Company, Texas Relocation Company, and Texas Seed Company Product Development Research Awards totaling $44,562,097. Dr. WalkerPeach will also present the proposed timeline and RFAs for the second cycle of FY 2020 as well as update the Oversight Committee on the proposed expansion of the Product Development Review Council by one member. CPRIT will not publicly disclose information related to the Product Development Research grant applications recommended for funding until the Oversight Committee meeting. The information is available to board members through a secure electronic portal. August 21, 2019 Oversight Committee Meeting Overview Summary Page 2 Chief Prevention and Communications Officer Report and Grant Award Recommendations Ramona Magid will update the Oversight Committee on the on the agency’s prevention activities and present the PIC’s ten award recommendations totaling $14,497,981. The recommended awards include Tobacco Control and Lung Cancer Screening; Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations; Evidence-Based Cancer Prevention Services; and Dissemination of CPRIT-Funded Cancer Control Interventions. Ms. Magid will also present the Prevention Program’s proposed timeline and RFAs for the second cycle of FY 2020. CPRIT will not publicly disclose information related to the Prevention grant applications recommended for funding until the Oversight Committee meeting. The information is available to board members through a secure electronic portal. Internal Auditor Report Weaver and Tidwell, CPRIT’s internal auditor, will provide an internal audit update and present an internal audit report concerning follow-up procedures for p-cards and procurement. Weaver and Tidwell will also present the FY 2020 audit plan. Appointments - Scientific Research and Prevention Programs Committee Mr. Roberts has provisionally appointed eight new members to CPRIT’s Scientific Research and Prevention Programs Committees. CPRIT’s statute requires the Oversight Committee to approve the CEO’s recommendations before the appointments are final. CPRIT has provided biographical sketches for the appointees for the Oversight Committee’s consideration. Appointments – Appointments to the Advisory Committees Mr. Roberts will present new appointments to the Advisory Committee on Clinical Trials and the Product Development Advisory Committee. In addition, Mr. Roberts will update the Oversight Committee on the University Advisory Committee membership. FY 2020 Honoraria Policy Mr. Roberts will present CPRIT’s FY 2020 honoraria policy for peer reviewers and discuss the proposed honoraria policy changes for each program. Health & Safety Code § 102.1062 Waivers Mr. Roberts will present the four conflict of interest waivers pursuant to Texas Health and Safety Code 102.1062. The FY 2020 waivers are for Don Brandy, Dr. John Hellerstedt, Will Montgomery, and the Review Council Members. The Oversight Committee approved similar waivers for these four for FY 2019. Resolution Transferring Management Authority to the Texas Treasury Safekeeping Trust Company CPRIT’s statute authorizes the agency to transfer asset management to the Texas Treasury Safekeeping Trust Company (Trust Company). CPRIT staff recommends the potential assets 2 August 21, 2019 Oversight Committee Meeting Overview Summary Page 3 generated by the award contract with AlloVir (formerly ViraCyte) transfer to the Trust Company on or after August 21. The resolution approves transfer of the AlloVir assets and delegates authority to CPRIT’s CEO to take all actions necessary to complete the transfer. Amendments to 25 TAC Chapter 703 Ms. Eckel will present the final order approving amendments to the agency’s Chapter 703 administrative rules, which the Oversight Committee provisionally approved at the May meeting. If approved, the amendments will become effective in September. Ms. Eckel will also present proposed changes to Chapter 703 administrative rules. Legal staff will bring back these rule changes to the Oversight Committee for final approval in November after the public has an opportunity to comment on the proposed rule changes. Chief Operating Officer Report and Contract Approvals Heidi McConnell will discuss the operating budget, performance measures, and debt issuance history for the third quarter of FY 2019. She will also present recommendations for contract approvals for the following services: an economic assessment of the cost of cancer in Texas, internal audit, strategic communications due diligence services, grant management support services, outside legal services, and the Texas Treasury Safekeeping Trust Company interagency contract. Subcommittee Business The Nominations subcommittee will consider new subcommittee assignments for all members for fiscal year 2020-2021. The Oversight Committee must vote to approve the changes to subcommittee membership. CPRIT will provide the proposed subcommittee assignments
Load more

Recommended publications
  • Special Edition Inside
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Inside: Feature articles from 2014-2015 Special Edition VISIT THE ASPET CAREER CENTER TODAY! WWW.ASPET.ORG/CAREERCENTER/ 4 5 12 21 30 41 WHAT YOU NEED: ASPET’S CAREER CENTER HAS IT 52 Jobseekers: Employers: No registration fee Searchable résumé database Advanced search options Hassle-free posting; online account management tools 61 Sign up for automatic email notifi cations of new jobs that Reach ASPET’s Twitter followers (over 1,000), match your criteria LinkedIn Members (over 2,000), and email subscribers (over 4,000) Free & confi dential résumé posting 71 Post to just ASPET or to entire NHCN network Access to jobs posted on the National Healthcare Career Network (NHCN) Sign up for automatic email notifications of new résumés that match your criteria Career management resources including career tips, coaching, résumé writing, online profi le development, Job activity tracking and much more ASPET is committed to your success: The ASPET Career Center is the best resource for matching job seekers and employers in the pharmacology and related health science fi elds. Our vast range of resources and tools will help you look for jobs, fi nd great employees, and proactively manage 9650 Rockville Pike, Bethesda, MD 20814-3995 your career goals. Main Office: 301.634.7060 www.aspet.org ASPET Career Center Full Page Ad 2015 Updated.indd 1 1/15/2016 3:18:16 PM The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. THE PHARMACOLOGIST VISIT THE ASPET CAREER CENTER TODAY! PRODUCTION TEAM Rich Dodenhoff Catherine Fry, PhD WWW.ASPET.ORG/CAREERCENTER/ Judith A.
    [Show full text]
  • Speaker Bios
    Moores UCSD Cancer Center Industry/Academia Translational Oncology Symposium Speaker Bios David R. Bentley, D.Phil. Vice President & Chief Scientist, Illumina, Inc. David Bentley, Ph.D., is Chief Scientist for Illumina’s Sequencing business. His major research interest is the study of human sequence variation. He was previously Head of Human Genetics and founding member of the Board of Management at the Wellcome Trust Sanger Institute where he played leading roles in the Institute’s contribution to the human genome referencing sequence, the SNP Consortium and the International HapMap Project. Dr. Bentley earned a degree in Natural Sciences from the University of Cambridge, took a DPhil at the University of Oxford, and is currently a Fellow of the Academy of Medical Sciences. Clara D. Bloomfield, M.D. Distinguished University Professor William G. Pace III Professor of Cancer Research Cancer Scholar and Senior Advisor, Ohio State University Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute Education &Academic Appointments: 1968 M.D. U Chicago; 1973-80, Assistant, Associate Prof. of Medicine, U Minnesota (U. MN), Minneapolis, MN; 1980-89 Prof. of Medicine, Div. of Oncology, U.MN; 1989-97 Prof. of Medicine & Chief, Div. of Oncology, State University of NY at Buffalo; 1989-97 Chair, Department of Medicine, Roswell Park Cancer Institute (RPCI), Buffalo, NY; 1997-2001 Director, Div. of Hematology & Oncology, Department of Internal Medicine, The Ohio State University College of Medicine & Public Health (OSU COMPH), Columbus, OH; 1997- William G. Pace III Endowed Chair in Cancer Research & Prof, OSU; 1997-2003 Director, Comprehensive Cancer Center (CCC) & Deputy Director, James Cancer Hospital & Solove Research Institute (JCH), OSU; 2003- Cancer Scholar & Senior Advisor, OSUCCC & JCH; 2006- Distinguished University Prof.
    [Show full text]
  • Appendix 1*) for Essential Information Very Well Illustrated in Google and Wikipedia
    Appendix 1*) For Essential Information Very Well Illustrated in Google and Wikipedia *) in Support of the Text with Literature Citations. Referrals to illustrations in Appendix 2. Cancer in the Plant. The insertion of the Agrobacterium tumefaciens circular plasmid T (transferred) DNA into the genome of its new host, the plant (Gelvin BS. Microbiol Molecular Biol Rev 2003;67:16–37). The plant cancer “crown gall” (agrocallus; Agrobacterial crown gall) consists of malignantly transformed cells replicating the agrobacterial T DNA plasmid (reviewed in postscript Table XXXV). For reference: Koncz C Mayerhofer R Koncz-Kálmán Zs et al EMBO J 1990;9:1337–1346. Transfer of potentially oncogenic bacterial genes and proteins to patients: Septicemic Bacteroides enterotoxigenic (Sinkovics J G & Smith JP Cancer 1970;25:663–671; Viljoen KS et al PLoS One 2015;10(3):e0119462); Bartonella bacilliformis etc (Guy L et al PLoS Genet 2013;9(3):e1003393; Harms A & Dehio C Clin Microbiol Rev 2012;25:42–78; Llosa M et al Trends Microbiol 2012;20:355–9; Minnick MF et al PLoS Negl Trop Dis 2014;6(7):e2919); Helicobacter pylori (Bonsor DA et al J Biol Chem 2015;pii:jbc.M115.641829; Su YL et al J Immunol 2015;194:3997–4007; Vaziri F et al Pathog Dis 2015;73(3). pii.ftu021); Porphyromonas gingivalis (Katz J et al Int J Oral Sci 2011;3:209–215); Tuberculous infections with A. tumefaciens in patients (Ramirez FC et al Clin Infect Dis 1992;15:938–940). DNA-binding Antibodies. DNA- (or RNA-) binding proteins use zink finger motifs, leucine zippers and winged (beta-sheet loops) helix-turn helix motifs (HTH, two helices separated by the loop, RNA/DNA-binding domains) in recognition of RNA/DNA receptors for attachment.
    [Show full text]
  • Emil Frei III, MD: in Memoriam (1924–2013)
    Cancer Obituary Research Emil Frei III, MD: In Memoriam (1924–2013) "Tackle a big problem and stay with it"—advice from Emil Frei II to Emil Frei III Emil Frei III (Tom) was probably the most admired Amer- pleura-pneumonia–like organism. They worked out the nature ican cancer researcher of his generation. His death marks the of the infection in the ear canal of the rat and how to cure it with end of an amazing journey in oncology, a field that was in its a new antibiotic, tetracycline. Tom credited this and subsequent infancy in February 1955 when he arrived at the National experience with Dr. Zubrod (after both had moved to NCI) with Cancer Institute (NCI; Bethesda, MD). During his long career, teaching him about rigorous measurement in clinical research he contributed importantly to the cure of childhood leukemia, and the importance of the laboratory in bringing science to the Hodgkin's disease and other lymphomas, breast cancer, and bedside. other malignancies. It would be appropriate to state that his When Tom arrived at the NCI in 1955 at the age of 31 years, he work and that of his colleagues' has saved and will save millions decided to focus on the treatment of leukemia. Quantitative of lives throughout the world. Born in St. Louis, Tom Frei grew studies on leukemia were lacking; the relative response rates up in a deeply religious family, surrounded by artists and to two known chemotherapeutic agents, methotrexate and musicians. The family business was the Emil Frei Art Glass 6-mercaptopurine, were unknown; and no one had defined Company, founded by his grandfather and managed by his partial and complete responses.
    [Show full text]
  • October 2, 2020 | 8:30 A.M.—5:30 P.M
    in Tumor Immunology and Cancer Immunotherapy Conference October 2, 2020 | 8:30 a.m.—5:30 p.m. Time Title Speaker Neli Ulrich, PhD 8:30 a.m. Welcome Executive Director, Comprehensive Cancer Center Huntsman Cancer Institute Antitumor Immune Responses Induced by PD-1 Antoni Ribas, MD, PhD 8:45 a.m. Blockade Therapy University of California Los Angeles Rational Tumor and Immune Cell Treatment Daniel Peeper, PhD 9:30 a.m. Combinations: A Functional Genomics Approach Netherlands Cancer Institute 10:15 a.m. Break Sandra D’Angelo, MD 10:30 a.m. Cancer Testis Antigens as Therapeutic Targets in Sarcoma Memorial Sloan Kettering Cancer Center New T Cell Receptors and Targets by Dissection of Andrew Sewell, PhD 11:15 a.m. Successful Cancer Immunotherapy Cardiff University Noon Lunch CAR T Cell-Based Combination Immunotherapy for Prasad S. Adusumilli, MD, FACS 1 p.m. Solid Tumors Memorial Sloan Kettering Cancer Center Overcoming Resistance to Immune Checkpoint Blockers Zihai Li, MD, PhD 1:45 p.m. by Targeting GARP-TGF-Beta Pathway The Ohio State University 2:30 p.m. Break From the Clinic to the Lab: Investigating Mechanisms of Padmanee Sharma, MD, PhD 2:45 p.m. Response and Resistance to Immune Checkpoint Therapy MD Anderson Cancer Center The Role of Gut and Tumor Microbiome in Response Jennifer Wargo, MD, MMSc 3:30 p.m. to Cancer Therapy MD Anderson Cancer Center 4:15 p.m. Break Ira Mellman, PhD 4:30 p.m. Mechanistic Basis of Cancer Immunotherapy Genetech Alana Welm, PhD 5:15 p.m. Closing Remarks Co-Director, Cell Response and Regulation Program Huntsman Cancer Institute SPEAKERS Prasad S.
    [Show full text]
  • AACR Settles Dispute with Toronto Hotels Over 2003 Annual Meeting
    Vol. 31 No. 15 April 15, 2005 © Copyright 2005 The Cancer Letter Inc. All rights reserved. Price $335 Per Year AACR Settles Dispute With Toronto Hotels Over 2003 Annual Meeting Cancellation By Kirsten Boyd Goldberg The American Association for Cancer Research has settled a legal dispute with the Toronto Convention Center and hotels, stemming from the AACR 2003 Aftermath: cancellation of its annual meeting in April 2003. NCI Provided $2 Million The convention center and 19 hotels sought $6.2 million Canadian To Pay Washington from AACR as payment under contracts for housing the estimated 16,000 Convention Center, scientists and others who were expected to attend the meeting. Other Expenses Two days before the event was scheduled to begin, AACR cancelled . Page 2 it, citing the outbreak of Severe Acute Respiratory Syndrome in Toronto. (Continued to page 2) Washington Roundup: In Brief: Senate Committee AACR To Honor Eight Scientists Delays Session At Annual Meeting In Anaheim On FDA Nominee The American Association for Cancer Research will honor several . Page 4 scientists at its annual meeting April 16-20, in Anaheim, Calif. David Livingston, deputy director, Dana-Farber/Harvard Cancer Center National Academies: and the Emil Frei Professor of Genetics and Medicine, Harvard Medical Report Defines School, will receive the AACR-G.H.A. Clowes Memorial Award for his Indicators Of Progress contributions to the understanding of the molecular basis of cancer. In Quality of Care Charles Sawyers, investigator, Howard Hughes Medical Institute and . Page 5 Peter Bing Professor of Medicine, University of California, Los Angeles, will be awarded the AACR-Richard and Hinda Rosenthal Foundation Award Oversight Needed for his research in molecularly-targeted therapy, with special emphasis on For Cord Blood Banks, signaling pathway abnormalities in cancer cells as targets for drug therapy.
    [Show full text]
  • A Tribute to Emil Frei III
    Obituary A tribute to Emil Frei III Dr. Emil Frei III, one of the fathers of be found) was opposed by Abraham Goldin combination chemotherapy for cancer, and Lloyd Law at the NCI as well as Howard died after a prolonged illness in May of Skipper and Frank Schabel at the Southern 2013. He was 89 years old (Figure 1). Research Institute in Alabama, who were Known to his colleagues, family, and experts in the drug treatment of leukemic friends as Tom, Frei was the emeritus cell lines and murine leukemia. They held director and emeritus physician-in-chief that combinations of drugs with different of the Dana-Farber Cancer Institute and targets given simultaneously provided the the Richard and Susan Smith Distin- only hope for sustained remissions, since guished Professor of Medicine emeritus most cancers have infinite ways of finding at Harvard Medical School. A highly dis- their way around single agents. Zubrod, tinguished clinical investigator, Frei held whose military medicine experience was in leadership positions of major responsibil- the malaria program of World War II, saw ity at the National Cancer Institute (NCI) childhood leukemia as the cancer equiva- in Bethesda, Maryland, and at the M.D. lent of malaria and agreed with the basic Anderson Cancer Center in Houston, scientists. He urged Frei and Freireich to Texas, before his appointment at Harvard. combine drugs as they were produced to Frei was born in St. Louis on February 21, treat leukemia in childhood, to collaborate 1924, where his paternal grandfather had with other like-minded physicians, and to founded Emil Frei and Associates, a well- train younger physicians to learn the new known stained glass company.
    [Show full text]
  • A History of Cancer Chemotherapy Vincent T
    AACR Centennial Series A History of Cancer Chemotherapy Vincent T. DeVita, Jr. and Edward Chu Yale Cancer Center, Yale University School of Medicine, New Haven Connecticut Abstract The Early Period of Cancer Drug Development The use of chemotherapy to treat cancer began at the start of A selected history and timeline of events related to the the 20th century with attempts to narrow the universe of development of cancer chemotherapy is shown in Fig. 1. The first chemicals that might affect the disease by developing methods four decades of the 20th century were primarily devoted to model to screen chemicals using transplantable tumors in rodents. development. The major limitations of drug discovery were two- It was, however, four World War II–related programs, and the fold: first, the development of models that could effectively be used effects of drugs that evolved from them, that provided the to reduce the vast repertoire of chemicals to those few that might impetus to establish in 1955 the national drug development have activity against cancer in humans, and second, the access to effort known as the Cancer Chemotherapy National Service clinical facilities to test such agents. Center. The ability of combination chemotherapy to cure acute A major breakthrough in model development occurred in the early childhood leukemia and advanced Hodgkin’s disease in the 1910s when George Clowes of Roswell Park Memorial Institute (RPMI) 1960s and early 1970s overcame the prevailing pessimism about in Buffalo, New York, Roswell Park Memorial Institute developed the the ability of drugs to cure advanced cancers, facilitated the first transplantable tumor systems in rodents.
    [Show full text]
  • Emil Frei III, MD: in Memoriam (1924–2013)
    Cancer Obituary Research Emil Frei III, MD: In Memoriam (1924–2013) "Tackle a big problem and stay with it"—advice from Emil Frei II to Emil Frei III Emil Frei III (Tom) was probably the most admired Amer- pleura-pneumonia–like organism. They worked out the nature ican cancer researcher of his generation. His death marks the of the infection in the ear canal of the rat and how to cure it with end of an amazing journey in oncology, a field that was in its a new antibiotic, tetracycline. Tom credited this and subsequent infancy in February 1955 when he arrived at the National experience with Dr. Zubrod (after both had moved to NCI) with Cancer Institute (NCI; Bethesda, MD). During his long career, teaching him about rigorous measurement in clinical research he contributed importantly to the cure of childhood leukemia, and the importance of the laboratory in bringing science to the Hodgkin's disease and other lymphomas, breast cancer, and bedside. other malignancies. It would be appropriate to state that his When Tom arrived at the NCI in 1955 at the age of 31 years, he work and that of his colleagues' has saved and will save millions decided to focus on the treatment of leukemia. Quantitative of lives throughout the world. Born in St. Louis, Tom Frei grew studies on leukemia were lacking; the relative response rates up in a deeply religious family, surrounded by artists and to two known chemotherapeutic agents, methotrexate and musicians. The family business was the Emil Frei Art Glass 6-mercaptopurine, were unknown; and no one had defined Company, founded by his grandfather and managed by his partial and complete responses.
    [Show full text]
  • Emil Freireich, MD
    Emil Freireich, MD Session 1—October 5, 2011 About transcription and the transcript This interview had been transcribed according to oral history best practices to preserve the conversational quality of spoken language (rather than editing it to written standards). The interview subject has been given the opportunity to review the transcript and make changes: any substantial departures from the audio file are indicated with brackets [ ]. In addition, the Archives may have redacted portions of the transcript and audio file in compliance with HIPAA and/or interview subject requests. The views expressed in this interview are solely the perspective of the interview subject. They are not to be interpreted as the official view of any other individual or of The University of Texas MD Anderson Cancer Center. Chapter 00A Interview Identifier Tacey Ann Rosolowski, PhD 0:00:10.6 I am Tacey Ann Rosolowski, interviewing Dr. Emil J Freireich. It’s Emil, correct? Emil J Freireich, MD 0:00:17.8 Americans say “ee.” Tacey Ann Rosolowski, PhD 0:00:21.7 How would you like me to say it? Emil J Freireich, MD 0:00:23.1 J. 1 Interview Session: 01 Interview Date: October 5, 2011 Tacey Ann Rosolowski, PhD 0:00:23.4 J Freireich at the University of Texas MD Anderson Cancer Center in Houston, Texas. This interview is being conducted for the Making Cancer History Voices Oral History Project, run by the Historical Resources Center at MD Anderson. Dr. Freireich holds the Ruth Harriet Ainsworth Chair in Developmental Therapeutics. He is also a distinguished teaching professor and director of special medical education programs as well as the director of the Adult Leukemia Research Program at the University of Texas MD Anderson Cancer Center.
    [Show full text]
  • A Tribute to Emil Frei III
    A tribute to Emil Frei III Edward J. Benz Jr., David G. Nathan J Clin Invest. 2013;123(8):3188-3189. https://doi.org/10.1172/JCI71579. Obituary Dr. Emil Frei III, one of the fathers of combination chemotherapy for cancer, died after a prolonged illness in May of 2013. He was 89 years old (Figure 1). Known to his colleagues, family, and friends as Tom, Frei was the emeritus director and emeritus physician-in-chief of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor of Medicine emeritus at Harvard Medical School. A highly distinguished clinical investigator, Frei held leadership positions of major responsibility at the National Cancer Institute (NCI) in Bethesda, Maryland, and at the M.D. Anderson Cancer Center in Houston, Texas, before his appointment at Harvard. Frei was born in St. Louis on February 21, 1924, where his paternal grandfather had founded Emil Frei and Associates, a well-known stained glass company. He attended St. Louis University and then joined the United States Navy in World War II. The Navy sent him to Colgate University and then to Yale University for medical training. He graduated from Yale Medical School in 1948 and later served in the Navy Medical Corps during the Korean War. In 1955, Frei and his close colleague Emil J. Freireich were recruited to the expanding clinical program at the NCI by Gordon Zubrod, then the newly appointed NCI clinical director. Supported by Zubrod’s superb guidance and defense, Frei and Freireich began their […] Find the latest version: https://jci.me/71579/pdf Obituary A tribute to Emil Frei III Dr.
    [Show full text]
  • Emil J. Freireich: Legend in Cancer Research (March 16, 1927–February 1, 2021)
    Bone Marrow Transplantation (2021) 56:1764–1767 https://doi.org/10.1038/s41409-021-01284-z OBITUARY Emil J. Freireich: Legend in cancer research (March 16, 1927–February 1, 2021) Hagop Kantarjian 1 Received: 1 March 2021 / Revised: 3 March 2021 / Accepted: 24 March 2021 / Published online: 13 May 2021 © The Author(s), under exclusive licence to Springer Nature Limited 2021 Emil J. Freireich was a trailblazing scientist and the founding father of modern cancer research and care. To many of us who knew him well, he was much more: an idol and hero, a daily inspirational role model, a mentor and often a third parent. As he did for hundreds of us, Freireich brought me from a distant country to the United States when I was a 24-year-old medical student for a 4-month elective rotation, then in 1981 as a fellow. He took us under his wing 1234567890();,: 1234567890();,: at the University of Texas MD Anderson Cancer Center, provided us with endless opportunities, and helped us become, for better or for worse, who we are today. President Obama’s book title “The Audacity of Hope” describes the two salient characteristics that define the arc of his life and career. Freireich was first and foremost infinitely hopeful and optimistic. He said: “Humans cannot live without hope. Hopelessness is the greatest trauma a person has to suffer.” He knew this firsthand, having been born in 1927 under merciless conditions in Chicago, and having lost his father when he was 2. In his 1997 oral history (preserved at the National Cancer Institute [NCI]), he said, “People born in that era are a special brand of people because they lived through one of the greatest economic dislocations in the history of our species—the Great Depression of 1929….
    [Show full text]